South African-founded health technology startup Healthleap has raised $38 million in seed and Series A funding to expand its artificial intelligence (AI) platform, which helps hospitals identify patients at risk of undiagnosed illnesses. The technology aims to improve patient care by flagging health risks that may otherwise go unnoticed, while helping hospitals reduce complications and costs.
The funding includes an $8 million seed round co-led by Sequoia Capital and First Round Capital, followed by a $30 million Series A round led by Hummingbird Ventures. Healthleap has not disclosed its valuation.
Founded in South Africa in 2022 by siblings Jemima and Josiah Meyer, the company initially developed a clinical nutrition tool for dietitians. It later expanded its focus to help hospitals identify patients who may be suffering from conditions that are not recognised early enough, including malnutrition and delirium.
AI Technology Helps Hospitals Identify Patients at Risk
Healthleap connects to hospital electronic health record systems and uses language models to analyse clinical notes alongside structured patient information, including laboratory results, vital signs, weights and medications.
This allows the platform to identify warning signs recorded in patients’ files, such as poor appetite, recent weight loss, muscle loss and difficulty swallowing. It combines these findings with other clinical information to flag patients who may require further assessment by their care teams.
CEO and co-founder Josiah Meyer explained that important warning signs can be missed when hospitals rely only on structured medical data.
“A patient’s chart holds two kinds of data. Labs, weights, and vital signs sit in structured fields, but the most telling signs sit in clinicians’ written notes: poor appetite, recent weight loss, muscle loss, trouble swallowing,” he said.
He added that the company is developing an approach to extract both positive and negative mentions of these clinical signs in a way that can be expanded across different conditions.
The platform is currently used in more than 50 hospitals, where it screens patients for conditions such as malnutrition and delirium. Healthleap has also developed programmes to identify aspiration pneumonia, pressure ulcers and the risk of readmission among patients with congestive heart failure. These programmes are undergoing further clinical validation.
The system analyses adult inpatients’ records overnight. Each morning, it provides risk scores through a dashboard that fits into existing hospital workflows.
“We don’t diagnose patients,” the company explains through its approach. Instead, the software highlights potential concerns for medical teams to review and assess.
Malnutrition is a key focus because it often goes undiagnosed and can affect recovery. Research suggests that 20% to 50% of hospital inpatients are malnourished. The condition has also been linked to longer hospital stays, poor wound healing, infections and increased risks of serious complications.
Hospital Growth and Funding to Support Expansion
Healthleap has expanded rapidly over the past year, growing from three hospital partners to more than 50. Its customers include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare. Meyer said the company’s revenue grew more than tenfold over the same period, although he did not disclose the figures.
The company sells three-year contracts priced according to the number of licensed beds at each hospital. It also offers outcome-based pricing, linking payments to measurable financial benefits validated by hospital finance teams.
Meyer said every customer had recorded at least five times the contract price in direct financial returns, with some reporting annual total returns exceeding 20 times the contract price.
At the Hospital of the University of Pennsylvania, Healthleap’s malnutrition programme generated an annualised financial impact of $23.8 million. This included $6.3 million in additional reimbursement and $17.5 million attributed to shorter hospital stays.
The new funding will support investment in engineering, product development, sales and customer success. Healthleap also plans to expand the number of conditions its platform can identify.
In the longer term, the company aims to cover more than 40 major health conditions and extend its technology beyond hospitals into outpatient services and home care.
The expansion could give healthcare providers more opportunities to identify risks earlier, support timely clinical intervention and improve the use of hospital resources. For Healthleap, the next stage will involve broadening its technology while continuing to validate its performance across more conditions and care settings.